In an interview conducted at the 2021 Genitourinary Cancers Symposium, Robert Jones, MD, PhD, University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, discusses recent updates from the Phase 3 POUT study. This study was designed to investigate outcomes in patients with upper tract urothelial cancer randomized to peri-operative gemcitabine-cisplatin chemotherapy or surveillance. Dr Jones notes that these data following extended follow-up demonstrate maintenance of the previously reported disease-free survival benefit. There was no statistically significant improvement in overall survival.